FutuRx was founded by Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc.-TVI and OrbiMed Israel Partners together with the Israeli Innovation Authority of the Ministry of Economy and later joined by Leaps by Bayer, the impact investments unit of Bayer AG. The FutuRx incubator is dedicated to the inception of early-stage biopharma ventures based on cutting edge science and supporting them in successful drug development FutuRx strives to be a catalyst for drug development by bridging the gap between concept and proof of concept through its dedicated system and structure. FutuRx's management, together with its founders, will establish and fully support companies via its in-house laboratory and management facility. FutuRx provides a unique model for supporting early-stage innovation, by combining expertise of FutuRx management team, and global capabilities of the founders, teamed with the Technological Incubators Program at the Israeli Innovation Authority. Companies established by FutuRx benefit from professional assistance by industry leading experts. These global capabilities facilitate the development of innovative technologies, on the way to safely turning them into cutting-edge products for the benefit of patients and healthcare providers.